Elastrin Therapeutics, Inc. is a South Carolina-based biotechnology startup that is working to develop a groundbreaking new treatment capable of reversing cardiovascular disease. Born out of research conducted by Dr. Naren Vyavahare, Hunter Endowed Chair and Professor of Bioengineering at Clemson University, in collaboration with Dr. Charles Rice, Professor of Biological Sciences at Clemson University, Elastrin Therapeutics is creating technologies designed to restore hardened and damaged arteries and tissue by targeting the elastic fiber that makes them work.
Since its inception, Elatsrin has been leveraging their platform technology to develop therapeutics that render calcified tissue and organs supple again. The targets of Elastrin’s therapeutic treatments include reversing calcification in the artery wall of heart valves and reversing the hardening of arteries in diabetic patients suffering from cardiovascular disease to prevent or delay the onset of kidney disease related to calcification. Through these treatments, Elastrin hopes to restore degraded elastin by removing the harmful calcification that stiffens arteries. Their platform significantly improves the effectiveness of medications used to treat cardiovascular disease and eliminates side effects by combining particle design with elastin targeting.
Over the years, Elastrin has made significant strides in the health industry with their research. The usefulness and potential of their technology on reversing the course of cardiovascular disease has been noted in a blog article by the Director of the National Institutes of Health. Currently, Elastrin is working on testing the efficacy at different stages of disease, validating efficacy and safety with dosing studies, and on-boarding additional medical and biotech partners.
For more information on Elastrin Therapeutics, Inc., click here.
